Aerie Pharmaceuticals reported $-33643000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Aerie Pharmaceuticals AERI:US $ -33643000 85.38M
Alimera Sciences ALIM:US $ -4147000 1.4M
Amarin AMRN:US -28307000 44.04M
Bluebird Bio BLUE:US $ -120346000 138.95M
Cara Therapeutics CARA:US $ -27911000 5.61M
Coherus Biosciences CHRS:US $ -80925000 41.38M
Endo International Ordinary Shares ENDP:US $ 120.25M 52.02M
Horizon Pharma HZNP:US 196.44M 99.18M
Insmed INSM:US $ -101451000 1.41M
JAZZ PHA JAZZ:US 87.55M 105.43M
Merk MRK:US $ 5059M 207M
Mirati Therapeutics MRTX:US $ -184218000 12.86M
Novartis NOVN:VX 3.15B 266M
Ophthotech OPHT:US $ -34670000 1.57M
Pacira Pharmaceuticals PCRX:US $ 21.73M 24.09M
Regeneron Pharmaceuticals REGN:US $ 1286.6M 1353.1M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 1.97M 26.43M
Teva Pharmaceutical Industries TEVA:US 789M 182M
Valeant Pharmaceuticals VRX:CN C$ 308M 145M
Zoetis ZTS:US $ 794M 197M